ACER Acer Therapeutics Inc.

23.61
-0.26  -1%
Previous Close 23.87
Open 24.04
Price To Book 4.47
Market Cap 237351047
Shares 10,052,988
Volume 23,548
Short Ratio
Av. Daily Volume 29,178

NewsSee all news

  1. Acer Therapeutics Announces In-license of Osanetant from Sanofi
  2. Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance
  3. Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS
  4. Opexa Therapeutics Enters Oversold Territory
  5. Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 19610196
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605483
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19603140
  4. 8-K - Current report 19512343
  5. 8-K - Current report 19500174

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 25, 2019.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
NDA filing planned for 2019.
ACER-001
Urea cycle disorder (UCD)

Latest News

  1. Acer Therapeutics Announces In-license of Osanetant from Sanofi
  2. Is This Biotech Stock Turning A Corner? Acer Pops On FDA Acceptance
  3. Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS
  4. Opexa Therapeutics Enters Oversold Territory
  5. Acer Therapeutics Appoints Salma Jutt as Chief Commercial Officer
  6. Acer Therapeutics to Present at the Evercore ISI HealthConX Conference
  7. Do Institutions Own Shares In Acer Therapeutics Inc (NASDAQ:ACER)?
  8. Opexa Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  9. Acer Therapeutics (ACER) Shares March Higher, Can It Continue?
  10. Why Opexa Therapeutics (ACER) Could Shock the Market Soon

SEC Filings

  1. CT ORDER - Confidential treatment order 19610196
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605483
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19603140
  4. 8-K - Current report 19512343
  5. 8-K - Current report 19500174
  6. 8-K - Current report 181251459
  7. 424B2 - Prospectus [Rule 424(b)(2)] 181199147
  8. EFFECT - Notice of Effectiveness 181199128
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter